Cipla Limited (CIPLA) — Announcement | 4 August 2026
Cipla announced that its US subsidiary InvaGen closed a USFDA inspection at its Hauppauge facility, completing a pre-approval review without new observations. The filing confirms regulatory closure but adds no financial impact or guidance.
About Cipla Limited (CIPLA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when CIPLA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track CIPLA — Free💡 Ask AI about this filing
📊 More CIPLA filings
- Announcement — 11 August 2026 Cipla announced its ESG ratings from SES and NSE on August 11, 2026, showing a slight improvement in...
- 🔴 Corporate Action — 31 July 2026 Cipla announced the allotment of 7,850 fully paid-up equity shares of INR 2 each under its ESOS 2013...
- Announcement — 27 July 2026 Cipla announced U.S. FDA approval for its generic version of Advair Diskus across all three strength...
- 🔴 Financial Results — 23 July 2026 Cipla reported consolidated revenue of INR 7,119 crores for Q1 FY27, up 2% YoY, with One India busin...
- 🟡 Board Meeting — 23 July 2026 Cipla announced board approval of key managerial personnel changes effective 24 July 2026, including...
🔥 Also filed on 4 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when CIPLA files new disclosures
Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track CIPLA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research